Chi DS, Eisenhauer EL, Lang J, Huh J, Haddad L, Abu-Rustum NR, Sonoda Y, Levine DA, Hensley M, Barakat RR (2006) What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol 103(2):559–64. https://doi.org/10.1016/j.ygyno.2006.03.051

Article  CAS  PubMed  Google Scholar 

du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J (2009) Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer 115(15):1234–44. https://doi.org/10.1002/cncr.24149

Article  CAS  PubMed  Google Scholar 

Ledermann JA, Matias-Guiu X, Amant F, Concin N, Davidson B, Fotopoulou C, González-Martin A, Gourley C, Leary A, Lorusso D, Banerjee S, Chiva L, Cibula D, Colombo N, Croce S, Eriksson AG, Falandry C, Fischerova D, Harter P, Joly F, Lazaro C, Lok C, Mahner S, Marmé F, Marth C, McCluggage WG, McNeish IA, Morice P, Nicum S, Oaknin A, Pérez-Fidalgo JA, Pignata S, Ramirez PT, Ray-Coquard I, Romero I, Scambia G, Sehouli J, Shapira-Frommer R, Sundar S, Tan DSP, Taskiran C, van Driel WJ, Vergote I, Planchamp F, Sessa C, Fagotti A (2024) ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease. Ann Oncol 35(3):248–266. https://doi.org/10.1016/j.annonc.2023.11.015

Article  CAS  PubMed  Google Scholar 

Chiva L, Ordas P, Mishra J, Ayhan A, Lee YY, Bogani G, Sp S, Lomnytska M, Stukan M, Fruscio R, Chura BF, Salcedo-Hernandez RA, De Iaco P, Haidopoulos D, Svintsitskiy V, Jain V, Stanciu P, Rawert FL, Akdemir C, Abdallah R, Chacon E, Minguez JA, Gil-Moreno A, Kharchenko K, Mofrad MH, Gebauer G, Díaz-Feijoo B, Scibilia G, Klaric M, Škof E, Saadeh FA, Mueller MD, Saarelainen S, Tejerizo García Á, Fotopoulou C, Coronado P, Dermikiran F, Goffin F, Tsolakidis D, Gonzalez-Martin A, SUROVA Study Group (2025) SUROVA study: global real-world treatment strategies and mortality risk prediction in advanced ovarian cancer. Int J Gynecol Cancer 35(12):102688. https://doi.org/10.1016/j.ijgc.2025.102688

Article  PubMed  Google Scholar 

Vergote I, Coens C, Nankivell M, Kristensen GB, Parmar MKB, Ehlen T, Jayson GC, Johnson N, Swart AM, Verheijen R, McCluggage WG, Perren T, Panici PB, Kenter G, Casado A, Mendiola C, Stuart G, Reed NS, Kehoe S, EORTC, MRC CHORUS study investigators (2018) Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. Lancet Oncol 19(12):1680–1687. https://doi.org/10.1016/S1470-2045(18)30566-7

Article  PubMed  Google Scholar 

Fagotti A, Ferrandina MG, Vizzielli G, Pasciuto T, Fanfani F, Gallotta V, Margariti PA, Chiantera V, Costantini B, Gueli Alletti S, Cosentino F, Scambia G (2020) Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850). Int J Gynecol Cancer 30(11):1657–1664. https://doi.org/10.1136/ijgc-2020-001640

Article  PubMed  Google Scholar 

Aronson SL, Lopez-Yurda M, Koole SN, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, de Hingh IHJT, van Gent MDJM, Arts HJG, van Ham MAPC, van Dam PA, Vuylsteke P, Aalbers AGJ, Verwaal VJ, Van de Vijver KK, Aaronson NK, Sonke GS, van Driel WJ (2023) Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1): final survival analysis of a randomised, controlled, phase 3 trial. Lancet Oncol 24(10):1109–1118. https://doi.org/10.1016/S1470-2045(23)00396-0

Article  CAS  PubMed  Google Scholar 

Tugan Bese E, Bicer BO, Kayan SS, Cebi AS, Acikgoz H, Turna (2024) Fuat Demirkiran; 3–4 Cycles versus 6 Cycles Neoadjuvant Chemotherapy in Advanced-Stage Epithelial Ovarian Cancer: Survival Is Not Determined by the Number of Neoadjuvant Chemotherapy Cycles. Chemotherapy 4 June ; 69 (2): 122–132. https://doi.org/10.1159/000535755

Cummings M, Nicolais O, Shahin M (2022) Surgery in advanced ovary cancer: primary versus interval cytoreduction. Diagnostics (Basel) 12(14):988. https://doi.org/10.3390/diagnostics12040988

Article  PubMed  PubMed Central  Google Scholar 

Marchetti C, De Felice F, Romito A, Iacobelli V, Sassu CM, Corrado G, Ricci C, Scambia G, Fagotti A (2021) Chemotherapy resistance in epithelial ovarian cancer: mechanisms and emerging treatments. Semin Cancer Biol 77:144–166. https://doi.org/10.1016/j.semcancer.2021.08.011

Article  CAS  PubMed  Google Scholar 

Solass W, Kerb R, Mürdter T et al (2014) Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy. Ann Surg Oncol 21(2):553–559

Article  PubMed  Google Scholar 

Mehta S, Kammar P, Patel A et al (2022) Feasibility and safety of taxane-PIPAC in patients with peritoneal malignancies-a retrospective bi-institutional study. Indian J Surg Oncol 14(7):1–9. https://doi.org/10.1007/s13193-022-01641-4

Article  PubMed  PubMed Central  Google Scholar 

Larbre V, Alyami M, Mercier F, Vantard N, Bonnefoy I, Opsomer MA, Villeneuve L, Bakrin N, Rioufol C, Glehen O, Kepenekian V (2018) No renal toxicity after repeated treatment with pressurized intraperitoneal aerosol chemotherapy (PIPAC) in patients with unresectable peritoneal metastasis. Anticancer Res 38(12):6869–6875. https://doi.org/10.21873/anticanres.13062

Article  CAS  PubMed  Google Scholar 

Di Giorgio A, Macrì A, Ferracci F, Robella M, Visaloco M, De Manzoni G, Sammartino P, Sommariva A, Biacchi D, Roviello F, Pastorino R, Pires Marafon D, Rotolo S, Casella F, Vaira M (2023) 10 years of pressurized intraperitoneal aerosol chemotherapy (PIPAC): a systematic review and meta-analysis. Cancers (Basel) 15(9):1125. https://doi.org/10.3390/cancers15041125

Article  PubMed  PubMed Central  Google Scholar 

Fagotti A, Fanfani F, Ludovisi M, Lo Voi R, Bifulco G, Testa AC et al (2005) Role of laparoscopy to assess the chance of optimal cytoreductive surgery in advanced ovarian cancer: a pilot study. Gynecol Oncol 96:729–35

Article  PubMed  Google Scholar 

de Bree E, Michelakis D, Stamatiou D, Romanos J, Zoras O (2017) Pharmacological principles of intraperitoneal and bidirectional chemotherapy. Pleura Perit 2(1):47–62. https://doi.org/10.1515/pp-2017-0010

Article  Google Scholar 

Bijelic L, Stuart OA, Sugarbaker P (2012) Adjuvant bidirectional chemotherapy with intraperitoneal pemetrexed combined with intravenous Cisplatin for diffuse malignant peritoneal mesothelioma. Gastroenterol Res Pract 2012:890450. https://doi.org/10.1155/2012/890450

Article  PubMed  PubMed Central  Google Scholar 

Perioperative Safety and Tolerability of Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) with Concurrent Systemic Therapy in the Same Admission as a Bidirectional Chemotherapy. A Retrospective Comparative Study

Katdare N, Prabhu R, Mishra S, Mehta S, Bhatt A (2019) Pressurized intraperitoneal aerosol chemotherapy (PIPAC): initial experience from Indian Centers and a review of literature. Indian J Surg Oncol 10(1):24–30. https://doi.org/10.1007/s13193-018-0771-5

Article  PubMed  Google Scholar 

EP290/#660 First, Somashekhar S report of clinical outcomes with escalated doses of cisplatin and doxorubicin in PIPAC for peritoneal carcinomatosis of epithelial ovarian cancer. Int J Gynecol Cancer 32:A170

U.S. Department of Health and Human Services Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Bethesda (MD): National Institutes of Health, National Cancer Institute; 2017 Nov. Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm

Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, de Santibañes E, Pekolj J, Slankamenac K, Bassi C, Graf R, Vonlanthen R, Padbury R, Cameron JL, Makuuchi M (2009) The clavien-dindo classification of surgical complications: five-year experience. Ann Surg 250(2):187–96. https://doi.org/10.1097/SLA.0b013e3181b13ca2

Article  PubMed  Google Scholar 

Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RH, van der Burg ME, Lacave AJ, Panici PB, Kenter GG, Casado A, Mendiola C, Coens C, Verleye L, Stuart GC, Pecorelli S, Reed NS, European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group, NCIC Clinical Trials Group (2010) Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 363(10):943–53. https://doi.org/10.1056/NEJMoa0908806

Article  CAS  PubMed  Google Scholar 

Hanker LC, Loibl S, Burchardi N, Pfisterer J, Meier W, Pujade-Lauraine E, Ray-Coquard I, Sehouli J, Harter P, du Bois A, AGO and GINECO study group (2012) The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy. Ann Oncol 23(10):2605–2612. https://doi.org/10.1093/annonc/mds203

Article  CAS  PubMed  Google Scholar 

Vizzielli G, Giudice MT, Nardelli F, Costantini B, Salutari V, Inzani FS, Zannoni GF, Chiantera V, Di Giorgio A, Pacelli F, Fagotti A, Scambia G (2024) Pressurized intraperitoneal aerosol chemotherapy (PIPAC) applied to platinum-resistant recurrence of ovarian tumor: a single-institution experience (ID: PARROT Trial). Ann Surg Oncol 31(2):1207–1216. https://doi.org/10.1245/s10434-023-14648-0

Article  PubMed  Google Scholar 

Orgad R, Bakrin N, Bonnefoy I, Villeneuve L, Alyami M, Alhadeedi O, Glehen O, Kepenekian V (2026) Number of pressurized intraperitoneal aerosol chemotherapy (PIPAC) treatments is associated with longer survival: analysis of a large prospective cohort of patients with unresectable peritoneal surface malignancies. Ann Surg 283(3):505–512. https://doi.org/10.1097/SLA.0000000000006447

Article  PubMed  Google Scholar 

Girshally R, Demtröder C, Albayrak N, Zieren J, Tempfer C, Reymond MA (2016) Pressurized intraperitoneal aerosol chemotherapy (PIPAC) as a neoadjuvant therapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J Surg Oncol 14(1):253. https://doi.org/10.1186/s12957-016-1008-0

Article  PubMed  PubMed Central  Google Scholar 

Kefleyesus A, Bhatt A, Escayola C, Khomyakov V, Hübner M, Reymond MA, Thieme R, Sgarbura O, Willaert W, Ceelen W, Di Giorgio A, Vizzielli G, Glehen O, Robella M, Bakrin N (2023) Descriptive review of current practices and prognostic factors in patients with ovarian cancer treated by pressurized intraperitoneal aerosol chemotherapy (PIPAC): a multicentric, retrospective, cohort of 234 patients. Front Oncol 13:1204886. https://doi.org/10.3389/fonc.2023.1204886

Article  PubMed  PubMed Central